Immuno-oncology therapies, including immune checkpoint inhibitors targeting programmed death-1/death ligand 1 (PD-[L]1) and cytotoxic T lymphocyte antigen-4, have improved clinical outcomes across many tumor types1–3. The gene discussed is CD274; the disease is neoplasm.